Safety and Effectiveness of Tramadex-OD After Knee Arthroscopy
|ClinicalTrials.gov Identifier: NCT01024348|
Recruitment Status : Unknown
Verified February 2010 by Shaare Zedek Medical Center.
Recruitment status was: Not yet recruiting
First Posted : December 2, 2009
Last Update Posted : February 2, 2010
Extended-release tramadol is indicated for the management of moderate to severe pain in adults who require around-the-clock treatment. It provides an extended duration of action, more constant plasma concentrations, a reduced dosing frequency, and the potential for improved compliance and therapeutic outcomes.
The present study was designed to evaluate the safety and effectiveness of this medication in the treatment of early postoperative pain after knee arthroscopy.
|Condition or disease||Intervention/treatment||Phase|
|Postoperative Pain||Drug: extended-release tramadol Drug: paracetamol||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Open-label Study of the Safety and Effectiveness of Short-term Therapy With Extended-release Tramadol (TRAMADEX-OD) in the Management of Pain After Knee Arthroscopy.|
|Study Start Date :||December 2009|
|Estimated Primary Completion Date :||December 2010|
|Estimated Study Completion Date :||December 2011|
Active Comparator: Tramadex-OD
Patients will undergo knee arthroscopy under spinal anesthesia without any opioid. 30 minutes prior to surgery and 24 hours afterwards, patients will take a tablet of 100 mg Tramadex-OD. Breakthrough pain will be managed with 1 gr paracetamol (per os) as needed.
Drug: extended-release tramadol
30 minutes prior vto surgery and 24 hours afterwards, patients will take a tablet of 100 mg TRAMADEX-OD
Active Comparator: Control group
Patients will undergo knee arthroscopy under spinal anesthesia without any opioid.Postoperative pain will be managed throughout the study with 1 gr paracetamol (per os) every 6 hours as required.
in the control group, postoperative pain will managed with 1 gr paracetamol (per os) as needed (up to 4 times a day)
- Safety and effectiveness of TRAMADEX-OD will be evaluated by recording adverse events and using a visual analogue score for pain evaluation [ Time Frame: up to 48 hours ]
- Patient satisfaction will be evaluated by a telephone interview [ Time Frame: up to 48 hours ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01024348
|Contact: Yaacov Gozal, MDemail@example.com|
|Contact: Anna Lev, MDfirstname.lastname@example.org|
|Shaare Zedek Medical Center||Not yet recruiting|
|Jerusalem, Israel, 91031|
|Contact: Yaacov Gozal, MD 972-2-6555614 email@example.com|
|Principal Investigator: Yaacov Gozal, MD|
|Principal Investigator:||Yaacov Gozal, MD||Shaare Zedek Medical center, Jerusalem, Israel|